- Stocks Could Get a Short Post-Election Bounce
- Burger King Sales Strong, Despite Downturn
- EA Shares Skid After Videogame Maker Slashes Forecast
- Stock Picks: Tech, Retail, Beer & More
- Treasurys Flat as Economic Gloom Prevails
- Commodities Prices Get Pummeled During October
- Banks Must Use Bailout Funds for Lending: Rep. Frank
- Coming Soon: Congress Is Back With 'Stimulus-2'
- Clorox Quarterly Earnings Top Expectations
- Lightning Round: Merck, Deere, Altria and More
- Your First Move For Monday November 3rd
- Lightning Round OT: Morgan Stanley, Solarfun Power and More
- Buy Boardwalk Pipeline
- Is It Splitsville for Marathon Oil?
- Week Ahead Web Extra
- Game Plan: Why the U.S. Still Needs Help
- Pops & Drops: General Motors, Citigroup...
- Now Onto November
- Latest recalls: Toys, blenders, treadmills
- Iraq earmarks $15 billion for reconstruction
- Hong Kong's Cathay Pacific to sell 5 planes
- Study: Media coverage favors Obama
- Sun-Times shareholder demands ouster of CEO
- Stocks end Oct. with worst performance in 21 years
- Contract talks extended with Cooper Tire and union
- Movers roundup: Cigna, Electronic Arts
- Molex Inc. buys 2 million shares from co-chairman
- American National Insurance sets 77-cent dividend
PLYMOUTH, Minn. - Medical device company ev3 said Friday that it narrowed its loss in the third quarter as its sales grew 65 percent.
The company reported a net loss of $7.3 million, or 7 cents a share, compared with a net loss of $36.5 million, or 60 cents per share, in the year-earlier quarter. The 2007 results included a $20.2 million charge.
Adjusted for special items, the company swung to a profit of $3.9 million, or 4 cents a share from a loss of $30.1 million, or 50 cents per share, the year earlier.
Analysts polled by Thomson Reuters expected the company to lose 10 cents per share for the quarter, on average. Analyst estimates typically do not include items.
Ev3's sales grew to $107.0 million for the quarter, primarily due to the acquisition of FoxHollow. Third-quarter revenue included $100 million in net product sales and $7 million in research collaboration revenue.
Shares of the company fell 1 cent to close at $6.47 Friday.

